Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Cellectar Biosciences ( (CLRB) ) has issued an update.
On June 18, 2025, Cellectar Biosciences announced a one-for-thirty reverse stock split approved by stockholders on June 13, 2025. This reverse stock split, effective June 24, 2025, will reduce the number of outstanding shares from 54,361,197 to approximately 1,812,040, affecting stock options, warrants, and preferred stock conversion ratios proportionately. The move aims to streamline the company’s stock structure without altering the percentage ownership of existing stockholders, except for fractional shares, which will be compensated in cash.
The most recent analyst rating on (CLRB) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on Cellectar Biosciences stock, see the CLRB Stock Forecast page.
Spark’s Take on CLRB Stock
According to Spark, TipRanks’ AI Analyst, CLRB is a Underperform.
Cellectar Biosciences faces significant financial challenges with no revenue generation and heavy reliance on external financing. Technical indicators suggest a bearish trend, and the company’s valuation is weakened by negative earnings. Although the earnings call highlighted some clinical and regulatory progress, these are overshadowed by financial and operational setbacks, leading to a below-average overall stock score.
To see Spark’s full report on CLRB stock, click here.
More about Cellectar Biosciences
Cellectar Biosciences is a late-stage clinical biopharmaceutical company focused on discovering and developing proprietary drugs for cancer treatment. The company leverages its Phospholipid Drug Conjugate™ (PDC) delivery platform to create targeted cancer treatments, aiming for improved efficacy and safety. Its product pipeline includes iopofosine I 131, CLR 121225, CLR 121125, and various preclinical and partnered PDC assets.
Average Trading Volume: 11,961,914
Technical Sentiment Signal: Sell
Current Market Cap: $17.61M
Learn more about CLRB stock on TipRanks’ Stock Analysis page.